Intellia Therapeutics has initiated a rolling submission of a biologics license application (BLA) to the FDA for lonvo-z (formerly NTLA-2002), an innovative CRISPR-based gene editing therapy aimed at treating hereditary angioedema (HAE). This one-time treatment inactivates the kallikrein B1 (KLKB1) gene to permanently reduce kallikrein and bradykinin levels, thereby addressing the underlying cause of HAE. The announcement follows positive topline results from the Phase 3 HAELO clinical trial, where a single dose of lonvo-z resulted in significant freedom from HAE attacks and the need for ongoing therapy in most patients over a six-month observation period.

The significance of these findings lies in the potential to transform HAE management. Current treatment options often involve chronic therapies that require frequent administration, leading to a substantial burden on patients. In contrast, lonvo-z’s mechanism of action through in vivo CRISPR gene editing offers a groundbreaking approach that could eliminate the need for continuous treatment. The therapy has already received multiple regulatory designations, including RMAT and Orphan Drug Designation, which may expedite its pathway to approval and patient access.

The concrete implication of this development is the potential shift in treatment paradigms for HAE and similar genetic disorders. If approved, lonvo-z could set a precedent for the use of CRISPR technology in clinical settings, influencing future research directions and drug development timelines for genetic therapies. This approach not only aims to alleviate the symptoms of HAE but also addresses the root cause, potentially paving the way for curative therapies in other genetic conditions. Intellia anticipates completing its BLA submission by late 2026, with a commercial launch targeted for early 2027, marking a significant milestone in the application of gene editing technologies in medicine.

Source: globenewswire.com